This payout is backed by a history of consistent growth and, importantly, by the company’s cash flow generation. However, this attractive yield exists within a context of significant operational and strategic challenges. The decline in revenues from COVID-19 products and the impending loss of exclusivity for several major drugs create a considerable hurdle for future top-line growth.
Revenue vs. Earnings
It employs roughly 79,000 people and is headquartered in New York state. Positive developments in the oncology pipeline include a U.S. Food and Drug Administration (FDA) approval for Adcetris in large B-cell lymphoma and encouraging clinical data for Padcev in urothelial cancer. Talzenna also showed positive overall survival data in prostate cancer, though an FDA advisory panel has raised questions about its broader application. The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.
Cash Flow
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
To achieve that, investors tend to allocate high-quality va… Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, …
Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. Prosper trading forex with the martingale strategy Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck, Pfizer, and Summit Therapeutics.
By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup. Outside of oncology, the Abrysvo RSV vaccine has seen expanded recommendations in Europe and the U.S., potentially increasing its market reach. However, the path of drug development is not without setbacks, as evidenced by the discontinuation of the oral GLP-1 candidate danuglipron in April 2025. In response to these revenue pressures, Pfizer is actively pursuing a strategy centered on pipeline rejuvenation, with a pronounced focus on oncology. A cornerstone of this strategy was the $43 billion acquisition of Seagen in March 2023. Pfizer reported revenues of $13.72 billion in the last reported quarter, representing a year-over-year change of -7.8%.
The stock’s best cryptocurrency brokers EV/EBITDA ratio is 7.69, with an EV/FCF ratio of 15.98. On Oct. 29, 2021, the FDA extended the EUA for the vaccine to include children ages 5–11. U.S. lawmakers on Thursday asked Pfizer Inc for information on alleged comments by a former executive suggesting its research executives intentionally delayed clinical trial results of its COVID-19 va… CNBC’s Angelica Peebles joins ‘Squawk Box’ to report on the latest news. Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics’ Ivonescimab outperforming Pembrolizumab in a Phase III trial.
- For investors, the decision hinges on balancing the allure of the current high yield against the uncertainties tied to Pfizer’s multi-year transition.
- Pfizer reported revenues of $13.72 billion in the last reported quarter, representing a year-over-year change of -7.8%.
- The drugmaker has been looking for a way back ever since — a product, or several, that can rack up billions in annual sales and help its top line move consistently in the right direction.
- The Motley Fool has positions in and recommends Merck, Pfizer, and Summit Therapeutics.
- A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations provided by a rival drugmaker.
Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries. Please bear with us as we address this and restore your personalized lists. MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… For investors, the decision hinges on balancing the allure of the current high yield against the uncertainties tied to Pfizer’s multi-year transition.
US House panel seeks information from Pfizer over alleged COVID vaccine delay
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. Ford Motor and Dow lead the list of stocks with the highest dividend yields in the S&P 500. The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion.
Pfizer hopes to boost its bottom line and margins thanks to these optimization efforts. These might not immediately impact its stock performance, but together with its pipeline goals, they could eventually lead to much stronger returns. Merck’s cancer medicine Keytruda, the world’s best-selling drug, is a monoclonal antibody. Recent developments suggest that ivonescimab, a bispecific being developed in the U.S. by Summit Therapeutics, could challenge Keytruda, especially in the vast non-small cell lung cancer (NSCLC) market.
Financial Highlights
Select to analyze similar companies using key performance metrics; select up to 4 stocks. While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Pfizer has a noteworthy track record, having increased its dividend for 16 consecutive years, a history that often appeals to investors looking for reliable and growing income. Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. For the current quarter, Pfizer is expected to post earnings of $0.57 per share, indicating a change of -5% from the year-ago quarter.
About MarketBeat
- We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
- SSGJ-707 is being developed to treat NSCLC, colorectal cancer, and gynecological tumors.
- CNBC’s Angelica Peebles joins ‘Squawk Box’ to report on the latest news.
- However, the path of drug development is not without setbacks, as evidenced by the discontinuation of the oral GLP-1 candidate danuglipron in April 2025.
- Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, treatme…
- Recent developments suggest that ivonescimab, a bispecific being developed in the U.S. by Summit Therapeutics, could challenge Keytruda, especially in the vast non-small cell lung cancer (NSCLC) market.
Despite recent underperformance, a “Buy” rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. In 2024, Pfizer’s revenue was $63.63 billion, an increase of 6.84% compared to the previous year’s $59.55 billion. Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat’s FREE daily newsletter. World War I caused best japanese stocks a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally.
This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general. Discover which analysts rank highest on predicting the price target of PFE. Discover which analysts rank highest for PFE overall weighted by direction, price target, and price movement.
EPS of $0.92 for the same period compares with $0.82 a year ago. Meanwhile, the company is also working on cutting its expenses. It’s on track to deliver $4.5 billion in cost savings by year-end, with even more coming through 2027.
However, whereas monoclonal antibodies target one specific antigen, bispecifics target two; in some cases, this can increase efficacy. This stock pays an annual dividend of $1.72, which amounts to a dividend yield of 7.29%. Please bear with us as we address this and restore your personalised lists.